このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Takeda Pharmaceutical 将来の成長

Future 基準チェック /36

Takeda Pharmaceutical利益と収益がそれぞれ年間21.8%と1.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に4.3% 21.6%なると予測されています。

主要情報

22.1%

収益成長率

21.8%

EPS成長率

Pharmaceuticals 収益成長	20.0%
収益成長率	1.5%
将来の株主資本利益率	4.2%
アナリストカバレッジ	Good
最終更新日	28 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BOVESPA:TAKP34 - アナリストの将来予測と過去の財務データ ( )JPY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	4,451,242	286,866	647,475	1,031,195	15
3/31/2026	4,354,108	215,870	635,948	998,649	17
3/31/2025	4,289,362	88,562	646,920	977,078	17
3/31/2024	4,263,762	144,067	235,614	716,344	N/A
12/31/2023	4,169,049	178,219	-129,035	731,449	N/A
9/30/2023	4,154,414	191,626	129,243	963,227	N/A
6/30/2023	4,113,631	301,398	180,765	985,315	N/A
3/31/2023	4,027,478	317,017	343,467	977,156	N/A
12/31/2022	3,944,611	274,525	817,615	1,059,047	N/A
9/30/2022	3,749,354	213,167	789,089	1,028,328	N/A
6/30/2022	3,591,868	197,389	798,367	1,040,488	N/A
3/31/2022	3,569,006	230,059	937,068	1,123,105	N/A
12/31/2021	3,465,991	438,515	902,309	1,148,481	N/A
9/30/2021	3,401,450	473,105	777,572	1,018,931	N/A
6/30/2021	3,345,565	431,178	793,645	1,031,928	N/A
3/31/2021	3,197,812	376,005	774,463	1,010,931	N/A
12/31/2020	3,199,240	180,631	608,015	795,408	N/A
9/30/2020	3,221,804	56,051	498,511	720,676	N/A
6/30/2020	3,243,917	119,743	479,618	694,824	N/A
3/31/2020	3,291,188	44,241	452,042	669,752	N/A
12/31/2019	3,236,697	13,275	402,421	601,798	N/A
9/30/2019	2,876,782	83,262	399,600	551,732	N/A
6/30/2019	2,496,511	63,959	266,965	408,797	N/A
3/31/2019	2,097,224	135,192	194,365	328,479	N/A
12/31/2018	1,780,976	110,414	221,992	336,742	N/A
9/30/2018	1,769,726	140,738	225,190	328,658	N/A
6/30/2018	1,772,125	120,339	207,862	343,761	N/A
3/31/2018	1,770,531	186,886	249,592	377,854	N/A
12/31/2017	1,785,773	190,172	N/A	376,566	N/A
9/30/2017	1,762,667	163,457	N/A	316,619	N/A
6/30/2017	1,746,286	160,202	N/A	285,157	N/A
3/31/2017	1,732,051	114,940	N/A	261,363	N/A
12/31/2016	1,729,967	132,194	N/A	-8,176	N/A
9/30/2016	1,754,130	150,081	N/A	42,293	N/A
6/30/2016	1,795,088	155,110	N/A	57,618	N/A
3/31/2016	1,807,378	80,166	N/A	25,491	N/A
12/31/2015	1,831,096	-111,874	N/A	203,553	N/A
9/30/2015	1,830,521	-152,827	N/A	192,836	N/A
6/30/2015	1,812,971	-154,591	N/A	189,123	N/A
3/31/2015	1,777,824	-145,775	N/A	182,517	N/A
12/31/2014	1,744,795	75,405	N/A	N/A	N/A
9/30/2014	1,714,694	103,390	N/A	240,094	N/A
6/30/2014	1,692,531	110,981	N/A	N/A	N/A
3/31/2014	1,691,685	106,658	N/A	148,335	N/A
12/31/2013	1,655,033	103,330	N/A	N/A	N/A
9/30/2013	1,598,674	76,159	N/A	120,224	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TAKP34の予測収益成長率 (年間21.8% ) は貯蓄率 ( 9.9% ) を上回っています。

収益対市場: TAKP34の収益 ( 21.8% ) はBR市場 ( 14% ) よりも速いペースで成長すると予測されています。

高成長収益: TAKP34の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: TAKP34の収益 ( 1.5% ) BR市場 ( 7.2% ) よりも低い成長が予測されています。

高い収益成長: TAKP34の収益 ( 1.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TAKP34の自己資本利益率は、3年後には低くなると予測されています ( 4.3 %)。

Takeda Pharmaceutical 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Recent updates

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘